PT2252148T - Métodos de tratamento da síndrome do intestino irritável - Google Patents

Métodos de tratamento da síndrome do intestino irritável

Info

Publication number
PT2252148T
PT2252148T PT97150205T PT09715020T PT2252148T PT 2252148 T PT2252148 T PT 2252148T PT 97150205 T PT97150205 T PT 97150205T PT 09715020 T PT09715020 T PT 09715020T PT 2252148 T PT2252148 T PT 2252148T
Authority
PT
Portugal
Prior art keywords
methods
bowel diseases
treating bowel
treating
diseases
Prior art date
Application number
PT97150205T
Other languages
English (en)
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2252148(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of PT2252148T publication Critical patent/PT2252148T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT97150205T 2008-02-26 2009-02-26 Métodos de tratamento da síndrome do intestino irritável PT2252148T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3167908P 2008-02-26 2008-02-26
US10280108P 2008-10-03 2008-10-03

Publications (1)

Publication Number Publication Date
PT2252148T true PT2252148T (pt) 2020-01-23

Family

ID=41016472

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97150205T PT2252148T (pt) 2008-02-26 2009-02-26 Métodos de tratamento da síndrome do intestino irritável

Country Status (15)

Country Link
US (3) US8309569B2 (pt)
EP (2) EP2252148B1 (pt)
KR (1) KR20100122937A (pt)
CN (1) CN101959412A (pt)
AU (1) AU2009219240B2 (pt)
BR (1) BRPI0908026B8 (pt)
CA (1) CA2716578A1 (pt)
DK (1) DK2252148T3 (pt)
ES (1) ES2727728T3 (pt)
MX (1) MX2010009197A (pt)
NZ (1) NZ587098A (pt)
PL (1) PL2252148T3 (pt)
PT (1) PT2252148T (pt)
RU (2) RU2519649C2 (pt)
WO (1) WO2009108814A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
AU2009219240B2 (en) 2008-02-26 2014-10-16 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CA2752020A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
CN102596250A (zh) * 2009-09-13 2012-07-18 萨利克斯药品有限公司 治疗肠易激综合征(ibs)的方法
AU2011218129A1 (en) * 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
CN103228662B (zh) * 2010-07-12 2016-08-10 萨利克斯药品有限公司 利福昔明的制剂及其用途
EP2773205B1 (en) * 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법
GB2520889A (en) * 2012-09-06 2015-06-03 Alvine Pharmaceuticals Inc Patient reported outcome instrument
CN104955457A (zh) * 2012-09-12 2015-09-30 萨利克斯药品公司 给予利福昔明而不产生抗生素耐药性的方法
CN105025717A (zh) * 2012-09-13 2015-11-04 萨利克斯药品公司 改善患有肝性脑病的受试者的长期生存和降低其再住院率的方法
MX2015003326A (es) 2012-09-17 2015-08-12 Cedars Sinai Medical Center Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
PT2983647T (pt) * 2013-04-12 2020-11-09 Alfasigma Spa Administração de aine e composições, métodos e sistemas relacionados
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
WO2015173697A1 (en) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
RU2605615C2 (ru) * 2014-07-15 2016-12-27 Общество с ограниченной ответственностью "Гелизовит" Ректальный поликомплексный гель для лечения язвенного колита, болезни крона, свищей и осложнений, вызванных этими заболеваниями
EA039096B1 (ru) * 2014-08-11 2021-12-03 Саликс Фармасьютикалз, ИНК. Способы лечения заболевания кишечника (срк)
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
RU2665945C1 (ru) * 2017-08-07 2018-09-05 Наталья Юрьевна Пшеничная Способ прогнозирования длительности диареи и выбора тактики лечения
KR20200086285A (ko) 2017-11-10 2020-07-16 코스모 테크놀러지스 리미티드 경구 리파마이신 sv 조성물
US20210079473A1 (en) * 2018-04-24 2021-03-18 Cedars-Sinai Medical Center Methods and systems for characterizing severe crohn's disease
RU2712943C1 (ru) * 2018-08-03 2020-02-03 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ профилактики туберкулеза при воспалительных заболеваниях кишечника
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
JP2022548788A (ja) 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド リファキシミン液体製剤
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease
EP4162928A1 (en) * 2021-10-05 2023-04-12 Cosmo Technologies Ltd. Rifamycin for the treatment of pouchitis, with an in-situ gelling formulation
IL311573A (en) * 2021-10-05 2024-05-01 Cosmo Technologies Ltd Remote enema GELLING ENEMA OF RIFAMYCIN for the treatment of pouchitis and ulcerative colitis
WO2024076257A2 (en) 2022-10-03 2024-04-11 Dikovskiy Alexander Vladimirovich Composition for treatment of diarrhea of bacterial, viral and bacterial and functional origins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167909A (en) 1961-04-24 1965-02-02 Thompson Ramo Wooldridge Inc Self-cooled rocket nozzle
US3132908A (en) 1962-04-02 1964-05-12 Carrier Corp Thrust bearing construction
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006093774A2 (en) * 2005-02-25 2006-09-08 Solvay Pharmaceuticals, Inc. Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2009219240B2 (en) 2008-02-26 2014-10-16 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
EP2781296B1 (de) 2013-03-21 2020-10-21 Corning Laser Technologies GmbH Vorrichtung und verfahren zum ausschneiden von konturen aus flächigen substraten mittels laser

Also Published As

Publication number Publication date
BRPI0908026A2 (pt) 2015-07-21
US8309569B2 (en) 2012-11-13
RU2010139475A (ru) 2012-04-10
AU2009219240B2 (en) 2014-10-16
WO2009108814A1 (en) 2009-09-03
BRPI0908026B8 (pt) 2021-05-25
EP3563850A1 (en) 2019-11-06
RU2014104362A (ru) 2015-08-20
US20160000765A1 (en) 2016-01-07
BRPI0908026B1 (pt) 2021-03-23
CN101959412A (zh) 2011-01-26
EP2252148A4 (en) 2014-02-26
MX2010009197A (es) 2010-11-22
DK2252148T3 (da) 2019-05-06
AU2009219240A1 (en) 2009-09-03
EP2252148B1 (en) 2019-03-20
US20110118295A1 (en) 2011-05-19
EP2252148A1 (en) 2010-11-24
PL2252148T3 (pl) 2019-09-30
RU2519649C2 (ru) 2014-06-20
CA2716578A1 (en) 2009-09-03
ES2727728T3 (es) 2019-10-18
KR20100122937A (ko) 2010-11-23
US20130137713A1 (en) 2013-05-30
NZ587098A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
PT2252148T (pt) Métodos de tratamento da síndrome do intestino irritável
IL257418A (en) Methods for treating addiction
HK1252140A1 (zh) 使用含三唑的大環內酯治療抗性疾病的方法
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
IL212348A0 (en) Treatment method
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
GB0817067D0 (en) Intestinal treatment
ZA201204845B (en) Agents for treating disease
HK1155086A1 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
HK1154797A1 (en) Composition for treating disease
GB0718684D0 (en) Treatment method
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
GB0818713D0 (en) Substances useful for treating diseases
GB0817809D0 (en) Agent for treating disease
GB0817811D0 (en) Agent for treating disease
GB0817810D0 (en) Agent for treating disease
GB0920933D0 (en) Agent for treating disease
GB0920940D0 (en) Agent for treating disease
GB0920942D0 (en) Agent for treating disease
ZA201000867B (en) Methods for treating dependence
ZA201102198B (en) Treatment method